Asia-pacific Ophthalmic Drugs Market Forecast 2023-2032

The Asia-Pacific ophthalmic drugs market is set to project a CAGR of 7.06% during the forecast period, 2023-2032. The expansion of the market is fueled by rising healthcare budgets and heightened investments in eye care services throughout the Asia-Pacific region, which enhance the availability and accessibility of ophthalmic drugs.

MARKET INSIGHTS

Vietnam, Australia & New Zealand, Thailand, China, Japan, South Korea, Indonesia, India, and Rest of Asia-Pacific are analyzed for the Asia-Pacific ophthalmic drugs market growth evaluation. The aging population in Japan stands out as a crucial factor propelling the Ophthalmic drugs market in the country. With a progressively increasing elderly demographic, Japan is witnessing a surge in age-related eye disorders such as cataracts, glaucoma, and age-related macular degeneration (AMD). This demographic transition is driving the demand for ophthalmic drugs aimed at managing and treating these prevalent conditions.

The growth of the market is significantly influenced by Japan's esteemed healthcare system. Recognized for its excellence, the Japanese healthcare system plays a pivotal role in fostering market expansion. The government of Japan actively advocates for healthcare research and development, leading to the creation of a multitude of ophthalmic drugs known for their effectiveness and adherence to the highest quality standards. The relentless pursuit of superior eye care has positioned Japan at the forefront of developing cutting-edge pharmaceuticals.

India is currently experiencing a rise in the incidence of eye disorders, such as cataracts, glaucoma, and age-related macular degeneration. This trend is attributed to factors like the aging population and lifestyle choices. The expansion of the country's healthcare infrastructure, including the establishment of eye care clinics and hospitals, has improved the availability of ophthalmic treatments, thereby bolstering the market. Ophthalmic drug manufacturers are placing emphasis on innovation by developing advanced formulations like preservative-free eye drops, extended-release implants, and combination therapies to offer effective treatment options.

COMPETITIVE INSIGHTS

Some of the key companies in the market are: Regeneron Pharmaceuticals Inc, Sun Pharmaceutical Industries Ltd, Santen Pharmaceutical Co Ltd, etc.

Our report offerings include:

Explore key findings of the overall market
Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
Market Segmentation caters to a thorough assessment of key segments with their market estimations
Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
The competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Product Code: 74034

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
- 2.4.1. IMPACT OF COVID-19 ON OPHTHALMIC DRUGS MARKET
2.5. MAJOR MARKET FINDINGS
- 2.5.1. EMERGING THERAPIES FOR DRY EYE SYNDROME
- 2.5.2. GROWING DEMAND FOR COMBINATION THERAPIES
- 2.5.3. INCREASING INVESTMENT IN RESEARCH & DEVELOPMENT
- 2.5.4. SHIFT TOWARD OVER-THE-COUNTER (OTC) PRODUCTS

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. AGING POPULATION'S SUSCEPTIBILITY TO AGE-RELATED EYE CONDITIONS
- 3.1.2. ADVANCEMENTS IN DRUG DELIVERY TECHNOLOGIES
- 3.1.3. RISING PREVALENCE OF EYE DISEASES AND DISORDERS
- 3.1.4. FAVORABLE REIMBURSEMENT POLICIES BY HEALTHCARE SYSTEMS
3.2. KEY RESTRAINTS
- 3.2.1. DELAY IN DRUG APPROVALS
- 3.2.2. SIDE EFFECTS RELATED TO OPHTHALMIC DRUGS

4. KEY ANALYTICS

4.1. KEY MARKET TRENDS
4.2. TECHNOLOGY SNAPSHOT
- 4.2.1. BIOLOGICS
- 4.2.2. CELL THERAPY
- 4.2.3. GENE THERAPY
- 4.2.4. DRUG DELIVERY
- 4.2.5. SMALL MOLECULE
- 4.2.6. OTHER TECHNOLOGIES
4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. KEY BUYING CRITERIA
4.8. REGULATORY FRAMEWORK

5. MARKET BY INDICATION

5.1. DRY EYE
5.2. GLAUCOMA
5.3. INFECTION/INFLAMMATION/ALLERGIES
5.4. RETINAL DISORDER
- 5.4.1. WET AGE-RELATED MACULAR DEGENERATION
- 5.4.2. DRY AGE-RELATED MACULAR DEGENERATION
- 5.4.3. DIABETIC RETINOPATHY
- 5.4.4. OTHER RETINAL DISORDERS
5.5. OTHER INDICATIONS

6. MARKET BY TYPE

6.1. PRESCRIPTION DRUGS
6.2. OVER-THE-COUNTER DRUGS

7. MARKET BY DOSAGE FORM

7.1. GELS
7.2. EYE SOLUTIONS & SUSPENSIONS
7.3. CAPSULES & TABLETS
7.4. EYE DROPS
7.5. OINTMENTS

8. MARKET BY THERAPEUTIC CLASS

8.1. ANTI-GLAUCOMA
8.2. ANTI-INFECTION
8.3. ANTI-INFLAMMATORY
8.4. ANTI-ALLERGY
8.5. OTHER THERAPEUTIC CLASSES

9. MARKET BY DISTRIBUTION CHANNEL

9.1. HOSPITAL PHARMACIES
9.2. DRUG STORES
9.3. ONLINE PHARMACIES
9.4. OTHER DISTRIBUTION CHANNELS

10. GEOGRAPHICAL ANALYSIS

10.1. ASIA-PACIFIC
- 10.1.1. MARKET SIZE & ESTIMATES
- 10.1.2. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET DRIVERS
- 10.1.3. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET CHALLENGES
- 10.1.4. KEY PLAYERS IN ASIA-PACIFIC OPHTHALMIC DRUGS MARKET
- 10.1.5. COUNTRY ANALYSIS
  - 10.1.5.1. CHINA
  - 10.1.5.1.1. CHINA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.1.5.2. JAPAN
  - 10.1.5.2.1. JAPAN OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.1.5.3. INDIA
  - 10.1.5.3.1. INDIA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.1.5.4. SOUTH KOREA
  - 10.1.5.4.1. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.1.5.5. INDONESIA
  - 10.1.5.5.1. INDONESIA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.1.5.6. THAILAND
  - 10.1.5.6.1. THAILAND OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.1.5.7. VIETNAM
  - 10.1.5.7.1. VIETNAM OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.1.5.8. AUSTRALIA & NEW ZEALAND
  - 10.1.5.8.1. AUSTRALIA & NEW ZEALAND OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.1.5.9. REST OF ASIA-PACIFIC
  - 10.1.5.9.1. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES

11. COMPETITIVE LANDSCAPE

11.1. KEY STRATEGIC DEVELOPMENTS
- 11.1.1. MERGERS & ACQUISITIONS
- 11.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 11.1.3. PARTNERSHIPS & AGREEMENTS
11.2. COMPANY PROFILES
- 11.2.1. ABBVIE INC
  - 11.2.1.1. COMPANY OVERVIEW
  - 11.2.1.2. PRODUCTS & SERVICES
  - 11.2.1.3. STRENGTHS & CHALLENGES
- 11.2.2. ACCUTOME INC
  - 11.2.2.1. COMPANY OVERVIEW
  - 11.2.2.2. PRODUCTS & SERVICES
  - 11.2.2.3. STRENGTHS & CHALLENGES
- 11.2.3. BAUSCH HEALTH COMPANIES INC
  - 11.2.3.1. COMPANY OVERVIEW
  - 11.2.3.2. PRODUCTS & SERVICES
  - 11.2.3.3. STRENGTHS & CHALLENGES
- 11.2.4. GENENTECH INC
  - 11.2.4.1. COMPANY OVERVIEW
  - 11.2.4.2. PRODUCTS & SERVICES
  - 11.2.4.3. STRENGTHS & CHALLENGES
- 11.2.5. JOHNSON & JOHNSON
  - 11.2.5.1. COMPANY OVERVIEW
  - 11.2.5.2. PRODUCTS & SERVICES
  - 11.2.5.3. STRENGTHS & CHALLENGES
- 11.2.6. THEA PHARMA INC
  - 11.2.6.1. COMPANY OVERVIEW
  - 11.2.6.2. PRODUCTS & SERVICES
  - 11.2.6.3. STRENGTHS & CHALLENGES
- 11.2.7. NOVARTIS AG
  - 11.2.7.1. COMPANY OVERVIEW
  - 11.2.7.2. PRODUCTS & SERVICES
  - 11.2.7.3. STRENGTHS & CHALLENGES
- 11.2.8. PFIZER INC
  - 11.2.8.1. COMPANY OVERVIEW
  - 11.2.8.2. PRODUCTS & SERVICES
  - 11.2.8.3. STRENGTHS & CHALLENGES
- 11.2.9. REGENERON PHARMACEUTICALS INC
  - 11.2.9.1. COMPANY OVERVIEW
  - 11.2.9.2. PRODUCTS & SERVICES
  - 11.2.9.3. STRENGTHS & CHALLENGES
- 11.2.10. SANTEN PHARMACEUTICAL CO LTD
  - 11.2.10.1. COMPANY OVERVIEW
  - 11.2.10.2. PRODUCTS & SERVICES
  - 11.2.10.3. STRENGTHS & CHALLENGES
- 11.2.11. SUN PHARMACEUTICAL INDUSTRIES LTD
  - 11.2.11.1. COMPANY OVERVIEW
  - 11.2.11.2. PRODUCTS & SERVICES
  - 11.2.11.3. STRENGTHS & CHALLENGES
- 11.2.12. TEVA PHARMACEUTICALS INDUSTRIES LTD
  - 11.2.12.1. COMPANY OVERVIEW
  - 11.2.12.2. PRODUCTS & SERVICES
  - 11.2.12.3. STRENGTHS & CHALLENGES